The Innovative Licensing and Access Pathway (ILAP) is a Medicines and Healthcare products Regulatory Agency (MHRA) initiative designed to provide developers of novel medicines with an optimised route to market, through enhanced engagement with key stakeholders in the process, from clinical adoption through to NHS adoption.
In this guide, the Cell and Gene Therapy Catapult (CGT Catapult) provides an overview of the ILAP initiative and its benefits, highlighting the required steps therapy developers must take to optimise the scheme to support successful adoption.
We have leveraged our experience in supporting collaborators through the ILAP to develop this guidance, helping therapy developers to optimise engagement with the scheme and the derived outputs, outcomes and impact on enhancing the probability for timely therapy adoption in the target population.
